Search Results
Your search for Matthew Stenger matches 581 pages
Showing 301 - 350Increased Breast Cancer Risk Reported in Childhood Sarcoma and Leukemia Survivors With No History of Chest Radiotherapy
In an analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Henderson et al found that childhood survivors of sarcoma and leukemia with no history of chest radiotherapy were at an increased risk of breast cancer. Increased Risk The study included data from...
Risk Factors for Lymphedema in Patients Treated for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Ferguson et al found that cellulitis in the affected arm, but not blood draws, injections, trauma to the affected arm, or air travel, was associated with an increased risk of lymphedema in women treated for breast cancer. Study Details In...
UK Study Suggests Association Between Screen-Detected Ductal Carcinoma in Situ and Reduced Invasive Interval Breast Cancers
In a UK retrospective population-based study reported in The Lancet Oncology, Duffy et al found a significant inverse association between the detection of ductal carcinoma in situ in breast cancer screening and the incidence of invasive interval cancers diagnosed within 3 years after screening....
Study Finds Adjuvant Anastrozole Reduces Recurrence Risk vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
In a phase III trial (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-35) reported in The Lancet, Margolese et al found that adjuvant anastrozole significantly improved the breast cancer–free interval vs tamoxifen in postmenopausal women with hormone receptor–positive...
No Association Seen Between New or Worsening Aromatase Inhibitor–Related Musculoskeletal or Vasomotor Symptoms and Relapse-Free Survival
Retrospective analyses of the ATAC, TEAM, and BIG 1-98 adjuvant endocrine therapy trials in breast cancer have suggested that treatment-emergent endocrine symptoms may be associated with superior survival outcomes. However, in a study reported in the Journal of Clinical Oncology, Stearns et al...
Use of 21-Gene Recurrence Score May Be Linked to Chemotherapy Use and Health-Care Costs in Women With Breast Cancer
In a study using Pennsylvania Cancer Registry data reported in the Journal of Clinical Oncology, Epstein et al found that use of the 21-gene recurrence score (RS) assay was associated with lower use of chemotherapy and lower medical spending among patients younger than age 55 with early-stage...
High Risk on Breast Cancer Risk Prediction Tools Associated With More Favorable Disease Characteristics
In a Swedish study reported in the Journal of Clinical Oncology, Holm et al found that high risk on the Tyrer–Cuzick predicted 10-year breast cancer risk score (TCRS) and a 77-single nucleotide polymorphism polygenic risk score (PRS) tended to be associated with favorable prognostic features...
Japanese Study Shows Oral Fluoropyrimidine S-1 Is Noninferior to Taxanes as First-Line Treatment of HER2-Negative Metastatic Breast Cancer
In a Japanese phase III trial (SELECT BC) reported in The Lancet Oncology, Takashima et al found that first-line treatment with the oral fluoropyrimidine S-1 was associated with noninferior overall survival vs taxane regimens in women with HER2-negative metastatic breast cancer resistant to...
Nonsignificant Improvement in Disease-Free Survival With Adjuvant Lapatinib/Trastuzumab vs Trastuzumab in Early HER2-Positive Breast Cancer
Results of a phase III trial, reported in the Journal of Clinical Oncology by Piccart-Gebhart et al, showed a modest and statistically nonsignificant increase in disease-free survival with concurrent adjuvant lapatinib (Tykerb) and trastuzumab (Herceptin) vs trastuzumab alone in patients with...
Telephone and In-Person Counseling for Weight Loss Effective in Women Treated for Breast Cancer
In the LEAN (Lifestyle, Exercise, and Nutrition) study reported in the Journal of Clinical Oncology, Harrigan et al found that telephone and in-person weight loss counseling was effective in reducing weight and C-reactive protein level in overweight or obese women treated for breast cancer. In the ...
Use of 21-Gene Recurrence Score vs Adjuvant! Online May Alter Chemotherapy Decisions in Breast Cancer
In a population-based cohort study in Ontario, Canada, reported in the Journal of Clinical Oncology, Levine et al found that use of the 21-gene recurrence score (RS) assay altered decisions regarding receipt of chemotherapy compared with use of Adjuvant! Online in patients with axillary...
No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases
In the phase II LUX-Breast 3 trial reported in The Lancet Oncology, Cortés et al found that afatinib (Gilotrif) alone or combined with vinorelbine did not increase patient benefit vs investigator choice of treatment in patients with HER2-positive breast cancer and progressive brain...
National Cancer Database Study Indicates Racial Differences in Neoadjuvant Chemotherapy Use in Women With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Killelea et al found that chemotherapy, particularly neoadjuvant chemotherapy, was more frequently given to black, Hispanic, and Asian women vs white women with stage I to III breast cancer, with the difference largely attributable to more...
Patient-Reported Outcomes With Adjuvant Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
As reported in The Lancet and at the recent San Antonio Breast Cancer Symposium, Ganz et al found differences in patient-reported outcomes with anastrozole vs tamoxifen in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial in postmenopausal women with hormone...
Potential Overdiagnosis of Contralateral Breast Cancer With Preoperative Magnetic Resonance Imaging in Older Women With Breast Cancer
In an analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare database reported in the Journal of Clinical Oncology, Wang et al found that use of preoperative magnetic resonance imaging (MRI) was associated with overdiagnosis of contralateral breast cancer among older...
Carpal Tunnel Syndrome in Patients Treated With Anastrozole in IBIS-II
As reported by Spagnolo et al in the Journal of Clinical Oncology, women receiving anastrozole in the International Breast Cancer Intervention Study II (IBIS-II) had a higher incidence of carpal tunnel syndrome compared with those receiving placebo. A higher incidence of carpal tunnel syndrome...
Study Finds No Improvement in Diagnostic Accuracy of Digital Screening Mammography With Computer-Aided Detection
In a study reported in JAMA Internal Medicine, Lehman et al found no difference in the diagnostic accuracy of digital screening mammography with vs without computer-aided detection. Study Details The study assessed the accuracy of digital screening mammography interpreted with (n = 495,818) vs...
Better Invasive Disease–Free Survival With Epirubicin/Cyclophosphamide and Docetaxel vs Epirubicin/Docetaxel and Capecitabine in Breast Cancer
In a Spanish phase III trial (GEICAM/2003-10) reported in the Journal of Clinical Oncology, Martín et al found that invasive disease–free survival was improved with adjuvant epirubicin/cyclophosphamide (EC) followed by docetaxel (EC-T) vs epirubicin/docetaxel followed by capecitabine...
Systematic Review Informing ACS Updated Guideline for Breast Cancer Screening in Women at Average Risk
Findings of a systematic review of the benefits and harms of breast cancer screening commissioned by the American Cancer Society (ACS) to inform its updated guideline on screening in average-risk women were reported in JAMA by Myers et al of the Duke Evidence Synthesis Group. Their findings were...
Chemotherapy-Induced Peripheral Neuropathy May Be Associated With Cerebral Perfusion and Gray Matter Changes
In a study reported in the Journal of Clinical Oncology, Nudelman et al found that increased chemotherapy-induced peripheral neuropathy symptoms at 1 month after completing treatment for breast cancer was associated with increased cerebral perfusion and increased gray matter density at 1 month....
Elevated C-Reactive Protein May Be Associated With Increased Breast Cancer Risk in Postmenopausal Women Not Using Hormone Therapy
In a study reported in the Journal of the National Cancer Institute, Gunter and colleagues found that increased levels of the inflammatory marker C-reactive protein (CRP) were associated with increased risk of breast cancer in postmenopausal women not using hormone therapy. No associations of...
Predicted Burden of Breast Cancer in the United States
In a study reported in Journal of the National Cancer Institute, Rosenberg et al predicted that the number of new invasive plus in situ breast cancers will increase from approximately 283,000 in 2011 to 441,000 in 2030. Modeling suggests that the proportion of estrogen receptor–negative cases ...
Less Favorable Characteristics for Breast Cancer Diagnosed After Biennial vs Annual Screening in Premenopausal Women
In a study reported in JAMA Oncology, Miglioretti et al found that diagnosis of breast cancer after biennial vs annual mammography screening was associated with a higher risk of less favorable tumor prognostic characteristics among premenopausal women. They also noted a nonsignificantly higher risk ...
Most Women Undergoing BRCA Genetic Testing Do Not Receive Pretest Genetic Counseling
In the ABOUT study reported in JAMA Oncology, Armstrong et al found that the majority of BRCA-tested women in a commercially insured population responding to a questionnaire about their experience had not received genetic counseling from a genetics clinician prior to testing. The study was...
Increasing Use of Preoperative Breast MRI Linked to Increased Postdiagnostic Imaging and Biopsy, Mastectomy, and Surgery Delay
In a Canadian population-based study reported in JAMA Oncology, Arnaout et al found that breast magnetic resonance imaging (MRI) is increasingly used in preoperative evaluation of women with breast cancer and that its use is associated with increased likelihood of confirmatory breast imaging,...
No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer
In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...
6-Year Incidence of Cardiac Events in NCCTG N9831/Alliance Adjuvant Trastuzumab Trial
As reported in the Journal of Clinical Oncology by Advani et al, the cumulative incidence of cardiac events remained significantly higher at 6 years in breast cancer patients who received adjuvant trastuzumab (Herceptin) in the NCCTG N9831/Alliance trial. However, few new congestive heart failure...
29-Year Single-Center Longitudinal Experience Indicates 2% Annual Risk of Breast Cancer in Lobular Carcinoma in Situ
As reported by King et al in the Journal of Clinical Oncology, 29-year longitudinal experience at Memorial Sloan Kettering Cancer Center indicates an annual 2% risk of breast cancer in women with lobular carcinoma in situ. Risk was reduced with chemoprevention. Study Details The study involved...
Reduced Risk of Estrogen Receptor–Negative Breast Cancer With Later Age at Menarche in African American Women
In a study reported in the Journal of the National Cancer Institute, Ambrosone et al found that risk of estrogen receptor–negative breast cancer was reduced with later age at menarche in both parous and nulliparous African American women. Greater interval between menarche and first live birth ...
12-Year Ipsilateral Breast Invasive Recurrence in 7.5% to 13.4% of Women With Low-Risk DCIS Receiving Surgical Excision Without Radiation
As reported by Solin et al in Journal of Clinical Oncology, 12-year results from the ECOG-ACRIN E5194 trial indicate that among women with ductal carcinoma in situ (DCIS) with low-risk clinical and pathologic characteristics, surgical excision without radiation therapy was associated with...
BMI Is an Independent Prognostic Factor in Patients With Node-Positive Breast Cancer Receiving Optimally Dosed Chemotherapy
In an analysis reported in the Journal of the National Cancer Institute, Ligibel et al found that body mass index (BMI) at diagnosis was independently prognostic for recurrence-free and overall survival in women with early-stage node-positive breast cancer who received doxorubicin,...
Comparison of Adjuvant Regimens in Early-Stage Breast Cancer
In a systematic review and network meta-analysis reported in JAMA Oncology, Fujii et al found that sequential anthracycline-cyclophosphamide and taxane (AC-T) appears to be the most effective adjuvant regimen in early-stage breast cancer in terms of association with overall survival and toxicity....
Breast Tumor Genomic Characteristics Suggest More Aggressive Biology in African American vs White Women
In a study reported in the Journal of Clinical Oncology, Keenan et al found that African American women with breast cancer had greater intratumor genetic heterogeneity, a higher frequency of TP53 mutation, and higher risk for basal tumors compared with white women, with the characteristics...
Phase II Study Suggests Survival Benefit With First-Line Fulvestrant vs Anastrozole in Advanced Breast Cancer
Overall survival data from a phase II study, reported in the Journal of Clinical Oncology by Ellis et al, suggest a benefit of first-line fulvestrant (Faslodex) vs anastrozole in postmenopausal women with estrogen receptor–positive advanced breast cancer. The study protocol was amended to...
Group-Based Behavioral Weight Loss Intervention Successful in Overweight/Obese Breast Cancer Survivors
Obesity increases the risk for overall and breast cancer mortality and comorbidity. As reported in the Journal of Clinical Oncology by Rock et al, the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) study has shown that a group-based behavioral intervention can produce...
Sham and Real Electroacupuncture Reduce Hot Flashes vs Gabapentin and Pill Placebo in Breast Cancer Survivors
In a study assessing placebo effects reported in the Journal of Clinical Oncology, Mao et al found that sham electroacupuncture produced a greater reduction in hot flashes than placebo pills and gabapentin, with the greatest reduction being achieved with real electroacupuncture. Study Details In...
Report of Secondary Outcomes in NSABP B-40 Indicates Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer
The phase III NSABP B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early HER2-negative breast cancer. In a report of secondary outcomes in The...
Introduction of Generic Aromatase Inhibitors Reduces Decline in Adherence in Medicare D Breast Cancer Patients Without Low-Income Subsidy
Adherence to aromatase inhibitor treatment for breast cancer declines over time. In a study reported in the Journal of the National Cancer Institute, Neuner et al found that introduction of generic aromatase inhibitors resulted in a reduction in decline in adherence among patients with breast...
Study Evaluates Breast Cancer Mortality in Women With DCIS
In a study reported in JAMA Oncology, Narod et al found that the risk of breast cancer mortality was elevated in some patients with ductal carcinoma in situ compared with the general population, with the risk being higher in younger vs older women and black vs white women. Approximately half of...
Hypofractionation of Breast Radiotherapy Associated With Reduced Acute Toxicity
In an analysis reported in JAMA Oncology, Jagsi et al found that hypofractionation of whole-breast radiotherapy was associated with reduced acute toxicity compared with conventional fractionation. Study Details The study involved data on physician-assessed toxic effects and patient-reported...
Most Stage-Specific Survival Improvement in Women With Breast Cancer Under Age 70 Is Not Explained by Tumor Size or Estrogen Receptor Status
In an analysis reported in the Journal of Clinical Oncology, Park et al found that most of the improvement in breast cancer–specific mortality observed over time in the United States is not explained by tumor size or estrogen receptor status in women aged < 70 years, suggesting a major...
Reduced Short-Term Effects With Hypofractionated Whole-Breast Irradiation After Breast-Conserving Surgery
In a randomized trial reported in JAMA Oncology, Shaitelman et al found that hypofractionated whole-breast irradiation resulted in reduced short-term effects compared with conventional fractionation in women with stage 0 to II breast cancer undergoing breast-conserving surgery. Study Details In...
17-Year Follow-up Indicates Early but Not Overall Reduction in Breast Cancer Mortality With Annual Mammography Screening at Age 40-49 Years
The 17-year follow-up in the UK Age trial, reported in The Lancet Oncology by Moss et al, indicated a reduction in breast cancer mortality during the first 10 years after diagnosis but not thereafter among women invited for annual mammography screening from age 40 to 49 years compared with...
ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Van Poznak et al, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer. The statement is based on an ASCO expert panel assessment of systematic reviews, ...
Benefit of Adjuvant Letrozole vs Tamoxifen Is Greater in Lobular Than in Ductal Breast Cancer
In a BIG 1-98 trial analysis reported in the Journal of Clinical Oncology, Metzger Filho et al found that the benefit of adjuvant letrozole vs tamoxifen was greater in patients with lobular than ductal breast carcinoma. Study Details In the BIG 1-98 trial, postmenopausal women with hormone...
Pretreatment TNF Level May Be Associated With Memory Impairment in Women With Newly Diagnosed Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Patel et al found that inflammatory cytokine levels were associated with poorer memory function in women with newly diagnosed breast cancer, with higher pretreatment levels of soluble tumor necrosis factor (TNF) receptor type ...
Improved Outcomes With Aromatase Inhibitors vs Tamoxifen in Early Breast Cancer
In a patient-level meta-analysis of randomized trials reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 5 years of aromatase inhibitor treatment significantly reduced the recurrence risk vs 5 years of tamoxifen therapy during the first 4 years and...
Adjuvant Bisphosphonates May Reduce Bone Recurrence and Breast Cancer Mortality in Postmenopausal Women
In a patient-level meta-analysis reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), adjuvant bisphosphonate treatment in early breast cancer was associated with a reduced risk of bone recurrence and breast cancer mortality, with the benefit limited to...
Phase II Study Evaluates Neoadjuvant Eribulin vs Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Locally Advanced HER2-Negative Breast Cancer
In a randomized phase II trial (NSABP FB9) reported in Breast Cancer Research and Treatment, Abraham and colleagues found no improvement in pathologic complete response rate with neoadjuvant eribulin (Halavan) vs weekly paclitaxel followed by doxorubicin/cyclophosphamide in women with locally...
NCIC MA.20 Trial: Addition of Regional Nodal Irradiation in Early Breast Cancer Improves Disease-Free but Not Overall Survival
In a phase III trial (National Cancer Institute of Canada [NCIC] Clinical Trials Group MA.20) reported in The New England Journal of Medicine, Whelan et al found that the addition of regional nodal irradiation to whole-breast irradiation did not improve overall survival in women with node-positive...
